GLP-1s Explained: Beyond the Weightloss with Dr. Kimberly Ferrero

Actuary Voices · Jun 25, 2026 · 1m

GLP-1 medications like Ozempic and Wegovy are making headlines for weight loss, but their potential impact goes far beyond the numbers on a scale. Could these drugs reshape health care spending, insurance coverage, longevity, and even the assumptions actuaries use to model risk? In this episode of Actuary Voices, Contingencies Editor-in-Chief Preeti Vasishtha speaks with Dr. Kimberly Ferrero, the American Academy of Actuaries' Assistant Director of Research. Drawing on her background in cardiovascular and metabolic disease research, Dr. Ferrero explores the science behind GLP-1 therapies, the…